JP7506607B2 - TfRに結合するバイスペシフィック抗体 - Google Patents

TfRに結合するバイスペシフィック抗体 Download PDF

Info

Publication number
JP7506607B2
JP7506607B2 JP2020562545A JP2020562545A JP7506607B2 JP 7506607 B2 JP7506607 B2 JP 7506607B2 JP 2020562545 A JP2020562545 A JP 2020562545A JP 2020562545 A JP2020562545 A JP 2020562545A JP 7506607 B2 JP7506607 B2 JP 7506607B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
tfr
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020562545A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020138487A1 (ja
JPWO2020138487A5 (cg-RX-API-DMAC7.html
Inventor
圭祐 三田村
了輔 中野
正之 甲斐
信明 高橋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Publication of JPWO2020138487A1 publication Critical patent/JPWO2020138487A1/ja
Publication of JPWO2020138487A5 publication Critical patent/JPWO2020138487A5/ja
Priority to JP2024096802A priority Critical patent/JP2024119984A/ja
Application granted granted Critical
Publication of JP7506607B2 publication Critical patent/JP7506607B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
JP2020562545A 2018-12-28 2019-12-27 TfRに結合するバイスペシフィック抗体 Active JP7506607B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024096802A JP2024119984A (ja) 2018-12-28 2024-06-14 TfRに結合するバイスペシフィック抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018248334 2018-12-28
JP2018248334 2018-12-28
PCT/JP2019/051594 WO2020138487A1 (ja) 2018-12-28 2019-12-27 TfRに結合するバイスペシフィック抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024096802A Division JP2024119984A (ja) 2018-12-28 2024-06-14 TfRに結合するバイスペシフィック抗体

Publications (3)

Publication Number Publication Date
JPWO2020138487A1 JPWO2020138487A1 (ja) 2021-11-11
JPWO2020138487A5 JPWO2020138487A5 (cg-RX-API-DMAC7.html) 2023-08-28
JP7506607B2 true JP7506607B2 (ja) 2024-06-26

Family

ID=71125764

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020562545A Active JP7506607B2 (ja) 2018-12-28 2019-12-27 TfRに結合するバイスペシフィック抗体
JP2024096802A Pending JP2024119984A (ja) 2018-12-28 2024-06-14 TfRに結合するバイスペシフィック抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024096802A Pending JP2024119984A (ja) 2018-12-28 2024-06-14 TfRに結合するバイスペシフィック抗体

Country Status (13)

Country Link
US (2) US12258413B2 (cg-RX-API-DMAC7.html)
EP (1) EP3903816A4 (cg-RX-API-DMAC7.html)
JP (2) JP7506607B2 (cg-RX-API-DMAC7.html)
KR (1) KR102991359B1 (cg-RX-API-DMAC7.html)
CN (1) CN113226371B (cg-RX-API-DMAC7.html)
AU (1) AU2019413278B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012569A2 (cg-RX-API-DMAC7.html)
CA (1) CA3125316A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021007797A (cg-RX-API-DMAC7.html)
MY (1) MY210422A (cg-RX-API-DMAC7.html)
SG (1) SG11202106990PA (cg-RX-API-DMAC7.html)
TW (2) TWI873112B (cg-RX-API-DMAC7.html)
WO (1) WO2020138487A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业(上海)股份有限公司 四价双特异性抗体、其制备方法和用途
JP7767613B2 (ja) 2021-11-15 2025-11-11 システィミューン,インコーポレイテッド 二重特異性抗体-カンプトテシン薬物複合体及びその製薬的使用
KR20250160363A (ko) * 2023-03-24 2025-11-12 바이오악틱 에이비 인간 트랜스페린 수용체 htfr1의 프로테아제-유사 도메인에 결합하는 항체
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법
IL327952A (en) * 2023-10-26 2026-06-01 Biogen Ma Inc Anti-transferrin receptor antibodies and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009131239A1 (ja) 2008-04-25 2009-10-29 Kyowa Hakko Kirin Co Ltd 安定な多価抗体
JP2014500886A (ja) 2010-11-30 2014-01-16 ジェネンテック, インコーポレイテッド 低親和性血液脳関門受容体抗体及びその使用
JP2015523336A (ja) 2012-05-21 2015-08-13 ジェネンテック, インコーポレイテッド 血液脳関門輸送の安全性を改善するための方法
JP2016526878A (ja) 2013-05-20 2016-09-08 ジェネンテック, インコーポレイテッド 抗トランスフェリン受容体抗体及び使用方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US570561A (en) 1896-11-03 S peters co
US2808035A (en) 1953-04-23 1957-10-01 Riley Stoker Corp Burning wet materials
JPS5623587A (en) 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
JPS58110600A (ja) 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
WO1985003934A1 (fr) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
JPS60221091A (ja) 1983-12-21 1985-11-05 Kyowa Hakko Kogyo Co Ltd 新規プロモ−タ−
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
JP2564268B2 (ja) 1985-08-28 1996-12-18 協和醗酵工業株式会社 融合抗原ポリペプチド
ZA872705B (en) 1986-04-22 1987-10-05 Immunex Corporation Human g-csf protein expression
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
JP2928287B2 (ja) 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
JP3131322B2 (ja) 1991-12-17 2001-01-31 協和醗酵工業株式会社 新規α2→3シアリルトランスフェラーゼ
US6042828A (en) 1992-09-07 2000-03-28 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
WO1994023021A1 (fr) 1993-03-29 1994-10-13 Kyowa Hakko Kogyo Co., Ltd. α-1,3-FUCOSYLTRANSFERASE
US5705614A (en) 1993-04-09 1998-01-06 Chiron Corporation Methods of producing antigen forks
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
PT2990420T (pt) * 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
PE20020132A1 (es) 2000-06-29 2002-03-04 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
EP1369431A4 (en) 2001-10-15 2005-01-12 Kirin Brewery ANTI-HLA-DR ANTIBODIES
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JP4958555B2 (ja) 2004-09-22 2012-06-20 協和発酵キリン株式会社 安定化されたヒトIgG4抗体
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US9221902B2 (en) * 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
CN102459344A (zh) * 2009-05-15 2012-05-16 中外制药株式会社 抗axl抗体
CN102803484A (zh) 2009-06-11 2012-11-28 大学共同利用机关法人情报·系统研究机构 生产蛋白质的方法
WO2011116387A1 (en) 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
US9206257B2 (en) 2011-04-19 2015-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
US9598496B2 (en) 2011-05-09 2017-03-21 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
SG10201704846VA (en) 2012-03-14 2017-07-28 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
US9388243B2 (en) 2013-05-29 2016-07-12 Samsung Electronics Co., Ltd. Method of target membrane protein depletion
TWI702316B (zh) * 2013-12-04 2020-08-21 日商中外製藥股份有限公司 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
AU2015242752A1 (en) * 2014-04-04 2016-10-20 Kyowa Hakko Kirin Co., Ltd. Anti-death receptor 3 (DR3) antagonistic antibodies with reduced agonistic activity
JP6779876B2 (ja) * 2014-11-19 2020-11-04 ジェネンテック, インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
EP3221361B1 (en) * 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
US20180016346A1 (en) * 2015-01-08 2018-01-18 Kyowa Hakko Kirin Co., Ltd Bispecific antibody binding to trailr2 and psma
AU2016282334B2 (en) * 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
TWI726897B (zh) * 2015-07-15 2021-05-11 日商協和麒麟股份有限公司 與人類crth2特異性結合之抗體
US20190161535A1 (en) * 2016-05-09 2019-05-30 Annexon, Inc. Compositions and methods for treating spinal muscular atrophy
KR102156626B1 (ko) 2018-07-16 2020-09-17 주식회사 셀바스에이아이 운동 처방 정보를 제공하는 서버 및 컴퓨터 프로그램

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009131239A1 (ja) 2008-04-25 2009-10-29 Kyowa Hakko Kirin Co Ltd 安定な多価抗体
JP2014500886A (ja) 2010-11-30 2014-01-16 ジェネンテック, インコーポレイテッド 低親和性血液脳関門受容体抗体及びその使用
JP2015523336A (ja) 2012-05-21 2015-08-13 ジェネンテック, インコーポレイテッド 血液脳関門輸送の安全性を改善するための方法
JP2016526878A (ja) 2013-05-20 2016-09-08 ジェネンテック, インコーポレイテッド 抗トランスフェリン受容体抗体及び使用方法

Also Published As

Publication number Publication date
WO2020138487A1 (ja) 2020-07-02
EP3903816A1 (en) 2021-11-03
EP3903816A4 (en) 2022-09-07
AU2019413278A1 (en) 2021-07-15
MY210422A (en) 2025-09-22
NZ777568A (en) 2025-05-02
JPWO2020138487A1 (ja) 2021-11-11
US20250250352A1 (en) 2025-08-07
TWI907249B (zh) 2025-12-01
SG11202106990PA (en) 2021-07-29
MX2021007797A (es) 2021-10-26
TWI873112B (zh) 2025-02-21
CA3125316A1 (en) 2020-07-02
TW202039581A (zh) 2020-11-01
KR20210108961A (ko) 2021-09-03
BR112021012569A2 (pt) 2021-09-14
US20220017635A1 (en) 2022-01-20
CN113226371B (zh) 2025-05-30
JP2024119984A (ja) 2024-09-03
US12258413B2 (en) 2025-03-25
CN113226371A (zh) 2021-08-06
AU2019413278B2 (en) 2026-04-09
KR102991359B1 (ko) 2026-07-16
TW202517296A (zh) 2025-05-01

Similar Documents

Publication Publication Date Title
US20240059788A1 (en) BISPECIFIC ANTIBODY WHICH BINDS TO CD40 AND EpCAM
KR101846590B1 (ko) 항 tim-3 항체
US20220259328A1 (en) Bispecific antibody binding to cd40 and fap
US20250250352A1 (en) BISPECIFIC ANTIBODY BINDING TO TfR
US20180016346A1 (en) Bispecific antibody binding to trailr2 and psma
JP7502281B2 (ja) Cd40とgpc3に結合するバイスペシフィック抗体
US20250092148A1 (en) Bispecific antibody that binds to cd116 and cd131
RU2810756C2 (ru) Биспецифические антитела, связывающиеся с tfr
WO2021261597A1 (ja) GPC3とTfRに結合するバイスペシフィック抗体
HK40062464A (en) Bispecific antibody binding to tfr
HK40038050A (en) Bispecific antibody which binds to cd40 and epcam

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240614